News

Rithmi
_
Explores
_
the
_
Adaption
_
of
_
its
_
Algorithm
_
through
_
the
_
Integration
_
of
_
Health
_
and
_
Activity
_
Data
_
from
_
Garmin®
_
Wearables

App development  ·  eHealth

The Valencian startup, endorsed by cardiologists and hospitals, has begun testing its algorithm with the technology of Cuatroochenta on data from consumer wearables

Rithmi, non-intrusive arrhythmia detector for stroke prevention, today announced it will explore adaptation of Rithmi algorithms through integration of health and activity data form Garmin® wearables. The Valencian startup has already been endorsed by cardiologists and hospitals across Sapain, and has received international recognition as an innovator in this market.

Rithmi aims to provide breakthrough CVD prevention services based on biometric data from consumer wearables, such as Garmin® activity bands and smartwatches. For the Valencian startup, this is the final step before a product launch, the result of three years of research and clinical trials. Rithmi expects to initiate the medical certification process as a CE-marked product for their services later this year.

The Rithmi algorithm analyzes data received from an external device with optical heart rate sensors, such as a Garmin® wearable. Based on this data, Rithmi can potentially detect atrial fibrillation (AF), the most common arrhythmia. The Rithmi services can then alert users AF has been detected and suggest they seek treatment by a clinician. This early detection and treatment can improve chances of avoiding further medical complications. Additionally, Rithmi provides an app that displays and saves all recorded data securely, offering the ability to share data with a doctor.

Rithmi has performed 190 successful clinical trials, with 97% accuracy, on patients from the Universitari i Politècnic Hospital La Fe of Valencia, under the leadership of arrhythmia specialist Dr Joaquín Oscá. Hospitals such as Vall d’Hebrón and Germans Trias i Pujol of Barcelona have already requested prototypes for internal use.

The smartband monitors patients based on algorithms, 24/h.

When the wristband detects a change in pulse, it sends a warning directly to the app that there ir an anomaly.

If a potential atrial fibrillation (AF) is detected, it notifies users so that they can contact their doctor fot further tests.

The app stores data and enables users to share results with others, such as the doctor.

The clinical trial success has led to recognition from several Spanish and European institutions, such as the Centre for Industrial Technological Development (CDTI), an organization under the Ministry of Science, Innovation and Universities, and the SME Instrument of the European H2020 program.

Rithmi is a Valencia-based company, created by entrepreneur Óscar Lozano in 2015, and backed by business promoter Blast Off Partners and Cuatroochenta as a technological partner, with financial coverage from various private investors. The project has recently been validated by CapitalCell, the European online investment platform specialized in biomedicine, where it keeps open a crowdfunding campaign to raise funds.